VIRX
Viracta Therapeutics, Inc. Common Stock
VIRX
VIRX
Delisted
VIRX was delisted on the 3rd of February, 2025.
41 hedge funds and large institutions have $14.1M invested in Viracta Therapeutics, Inc. Common Stock in 2023 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 7 increasing their positions, 11 reducing their positions, and 11 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more funds holding in top 10
Funds holding in top 10: →
less funds holding
Funds holding: →
less capital invested
Capital invested by funds: $ → $
36% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 11
64% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 11
Holders
41
Holding in Top 10
1
Calls
$9K
Puts
$3K
Top Buyers
| 1 | +$103K | |
| 2 | +$39.8K | |
| 3 | +$24.7K | |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$24K |
| 5 |
BlackRock
New York
|
+$17.8K |
Top Sellers
| 1 | -$2.36M | |
| 2 | -$477K | |
| 3 | -$255K | |
| 4 |
JRP
Jasper Ridge Partners
Menlo Park,
California
|
-$148K |
| 5 |
Millennium Management
New York
|
-$130K |